Improvement of Neuroenergetics by Hypertonic Lactate Therapy in Patients with Traumatic Brain Injury Is Dependent on Baseline Cerebral Lactate/Pyruvate Ratio. by Quintard, H. et al.
Improvement of Neuroenergetics by Hypertonic Lactate
Therapy in Patients with Traumatic Brain Injury Is Dependent
on Baseline Cerebral Lactate/Pyruvate Ratio
Herve´ Quintard,1,2,* Camille Patet,1,* Jean-Baptiste Zerlauth,3 Tamarah Suys,1 Pierre Bouzat,1,4 Luc Pellerin,5
Reto Meuli,3 Pierre J. Magistretti,6–8 and Mauro Oddo1
Abstract
Energy dysfunction is associated with worse prognosis after traumatic brain injury (TBI). Recent data suggest that
hypertonic sodium lactate infusion (HL) improves energy metabolism after TBI. Here, we specifically examined
whether the efficacy of HL (3h infusion, 30–40 lmol/kg/min) in improving brain energetics (using cerebral micro-
dialysis [CMD] glucose as a main therapeutic end-point) was dependent on baseline cerebral metabolic state (assessed
by CMD lactate/pyruvate ratio [LPR]) and cerebral blood flow (CBF, measured with perfusion computed tomography
[PCT]). Using a prospective cohort of 24 severe TBI patients, we found CMD glucose increase during HL was
significant only in the subgroup of patients with elevated CMD LPR >25 (n = 13; +0.13 [95% confidence interval (CI)
0.08–0.19] mmol/L, p < 0.001; vs. +0.04 [–0.05–0.13] in those with normal LPR, p = 0.33, mixed-effects model). In
contrast, CMD glucose increase was independent from baseline CBF (coefficient +0.13 [0.04–0.21] mmol/L when
global CBF was <32.5 mL/100 g/min vs. +0.09 [0.04–0.14] mmol/L at normal CBF, both p < 0.005) and systemic
glucose. Our data suggest that improvement of brain energetics upon HL seems predominantly dependent on baseline
cerebral metabolic state and support the concept that CMD LPR – rather than CBF – could be used as a diagnostic
indication for systemic lactate supplementation following TBI.
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Introduction
Cerebral energy dysfunction has recently emerged as animportant determinant of prognosis following traumatic brain
injury (TBI).1 Although the exact mechanisms are still not com-
pletely understood, clinical investigation using the intra-cerebral
microdialysis (CMD) technique has identified reduced cerebral ex-
tracellular glucose as a surrogate marker of post-TBI cerebral energy
dysfunction and outcome.2 Glucose is an essential substrate for the
brain and is also important for several pathways, which are crucial for
brain cell survival, for example, the pentose-phosphate pathway.3
Strategies to improve cerebral glucose therefore appear of potential
benefit in this setting.
Abundant experimental evidence has demonstrated that lactate
can function as an energy substrate for the brain, particularly in
conditions of increased energy demand, such as after TBI.4,5 Pre-
liminary clinical interventional trials using hypertonic sodium
lactate infusion (HL) in patients with TBI have shown HL can be
successfully used to reduce secondary intracranial hypertension6 or
as a valid alternative to mannitol for the treatment of elevated
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intracranial pressure (ICP).7 Using CMD monitoring, we have re-
cently shown that HL was effective in decreasing ICP and had
positive effects on cerebral energetics.8 Control of ICP and cerebral
glucose-sparing effects of HL provide the pathophysiological ra-
tionale for its potential utility in the treatment of acute brain injury.
Although HL may be a valid therapeutic intervention, the exact
conditions and potential indications for its utilization are still to be
better characterized. The CMD lactate/pyruvate ratio (LPR) is a
marker of tissue cerebral metabolic state. Elevated LPR >25 is a
marker of impaired cerebral oxidative metabolism and outcome
after TBI.9,10 The CMD LPR would therefore be an ideal marker to
identify subjects with high LPR who are more likely to benefit from
therapies aiming to improve neuroenergetics, such as HL. On the other
extent, themajority of animal and human data on HL is predominantly
focused on TBI,11 and only a few tested models of cerebral ische-
mia.12,13 Whether HL retains its efficacy in conditions of reduced
cerebral blood flow (CBF) has not been evaluated so far in humans.
The specific end-point of this prospective study was therefore to
examine in patients with severe TBI monitored with CMD the effect
of HL on cerebral energetics – using CMD glucose as an end-point
for treatment efficacy – according to baseline CMD LPR and CBF,
quantified by perfusion computed tomography CT (PCT).14,15
Methods
Patients
This was a prospective interventional study performed between
March 2012 and October 2014 on consecutive patients with severe
TBI admitted to the Department of Intensive Care Medicine,
Lausanne University Hospital, Lausanne, Switzerland. Subjects
had severe TBI (defined by a Glasgow Coma Scale score < 9), an
abnormal head CT scan (defined by a Marshall score ‡ 2), and
underwent intracranial monitoring – consisting of CMD and ICP –
as part of standard care. The present investigation specifically fo-
cused on the relationship between the sparing-glucose effect of HL
and patient CMD LPR and CBF: a subset of the cohort presented
here (15/24 patients) was described in our previous study.8 Ap-
proval for the study was obtained from the local Ethical Committee,
and informed consent was obtained from each patient’s next of kin
and from an independent physician.
Systemic monitoring
Patients were treated according to a written institutional algo-
rithm for the treatment of severe TBI, based on international
guidelines and as previously described by our group.16 Sedation-
analgesia consisted of propofol and sufentanil. Arterial blood
concentrations of glucose and lactate were collected hourly, si-
multaneously to CMD samples, using an intra-arterial catheter.
Cerebral microdialysis monitoring
Cerebral metabolic monitoring was performed using an intra-
parenchymal CMA 70 catheter with a 20 kDa cut-off, perfused with
artificial cerebrospinal fluid via a CMA 106 pump at a rate of
0.3 lL/min (CMA Microdialysis AB, Stockholm, Sweden). Brain
extracellular samples were collected every 60min and immediately
analyzed at the bedside for concentrations of glucose, lactate, and
pyruvate, using a kinetic enzymatic analyzer (ISCUSflex; CMA
Microdialysis AB). The CMD catheter was inserted in the operating
room by an experienced neurosurgeon through a multiple-lumen bolt
(Integra Neurosciences, Plainsboro, NJ) and was placed in the right
frontal lobe, in apparently normal sub-cortical white matter. Adjacent
to the CMD catheter, a Codman ICP monitor (Codman, Raynham,
MA) was inserted for continuous measurement of ICP. The appro-
priate location of all monitors was assessed by a follow-up head CT
scan, performed within the first 24 h from intensive care unit (ICU)
admission.
Perfusion CT
Perfusion acquisitions were realized during the first control head
CT scan, using a LightSpeed multi-detector row CT system (GE
Medical Systems, Milwaukee, WI). Scanning was initiated 5 sec
after injection of 50mL of iohexol (300mg/mL of iodine; GE
Healthcare Europe, Glattbrugg, Switzerland), perfused at a rate of
5mL/sec with the following parameters: 80 kV, 240mAs, 0.4 ro-
tations/sec, total duration of 50 sec. The series evaluated 16 adjacent
5-mm-thick sections of brain parenchyma. A dedicated software
(Brilliance Workspace Portal; Philips Medical Systems, Cle-
veland, OH), which employs the central volume principle using
deconvolution to measure mean transit time (MTT), was used.
Cerebral blood volume (CBV) was calculated from the time-
enhancement curves, and global CBF was derived from the
equation: CBF =CBV/MTT. Three-dimensional reconstruction
was processed with Carestream Vue PACS (Carestream Health,
Rochester, NY) using a series of the thin-slice enhanced brain
CT. Regions of interest (ROI) were selected in line with our
previous studies providing an accurate quantitative assessment of
CBV, MTT, and CBF of each hemisphere.14,15 A global value of
CBV, MTT, and CBF was calculated by averaging values from
right and left hemispheres. Post-processing of PCT data was
performed by an experienced neuroradiologist who was blinded
to CMD variables.
Study intervention
Intervention consisted of a continuous infusion of hypertonic so-
dium lactate (Na+ 1000mmol/L and lactate 1000mmol/L, prepared
by the Division of Pharmacy, CHUV, Lausanne, Switzerland), ad-
ministered over 3 h, at a concentration of 30–40lmol/kg/min, initi-
ated as soon as possible following PCT. Dosing and timing of the
therapy were based on previous clinical trials conducted on healthy
subjects17–19 and critically ill patients,20 aiming to reach a steady
concentration of arterial blood lactate of about 4–5mmol/L.
Data collection and processing
Patient characteristics and radiological variables included age,
admission Glasgow Coma Scale score, Marshall CT-scan score,
time from TBI to CMDmonitoring and to the start of HL, time from
PCT to the start of HL, and duration of intracranial monitoring.
Patients were categorized into two subgroups according to a)
baseline CMD LPR, using LPR >25 as the threshold of impaired
cerebral oxidative metabolism and increased energy demand, in line
Table 1. Patient Baseline Characteristics
Variable Value
Patient number 24
Age, years 38 [24–54]
Cause of injury, fall/RTC 8/16
Isolated TBI vs. polytrauma 17 vs.7
Decompressive craniectomy, yes/no 2/22
Admission Glasgow Coma Scale score 6 [5–8]
Marshall CT-score 2 [2–3]
Time from TBI to initiation of CMD monitoring, h 8 [6–16]
Time from TBI to initiation of HL, h 27 [22–41]
Time from PCT to initiation of HL, h 4 [2–18]
Duration of CMD monitoring, days 4 [3–7]
Data are expressed as median and interquartile range.
CMD, cerebral microdialysis; HL, hypertonic lactate infusion; PCT,
perfusion CT; RTC, road traffic collision; TBI, traumatic brain injury.
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with previous studies9,10; and b) baseline global CBF, dichotomized
as normal versus. oligemic, defined by a CBF <32.5mL/100 g/min.
This cut-off for global CBF was based on our previous PCT studies
in TBI patients and was set to be at least 2 standard deviations below
normal CBF.14,15
CMD samples were analyzed hourly, simultaneously to arterial
blood gas analysis. Baseline CMD values were defined as the single
value taken from the sample immediately preceding the start of HL.
Systemic values were recorded continuously and were then mat-
ched to timely CMD samples.
Statistical analysis
Dynamic hourly changes of arterial blood and CMD glucose and
lactate concentrations from baseline (T0), during HL (T0–3 h), and
up to 12 h were first graphically plotted. For comparisons, longi-
tudinal data analysis was used to account for repeated measures of
physiological variables over time across different patients. Statis-
tical analysis was conducted with a mixed-effects multi-level re-
gression model, with time entered as an independent variable and
allowing it to have a random intercept and a random slope ac-
cording to the patient. A correlation coefficient (with 95% CI) was
obtained, which corresponded to the change of the variable during
the time of HL. This analysis was conducted in the total population
and in predefined sub-groups. Statistical analyses were performed
using Stata 12 (Stata Corp., College Station, TX), and statistical
significance was set at p < 0.05.
Results
Patient characteristics
A total of 24 consecutive patients were studied. Baseline de-
mographic and physiological characteristics are presented in Table
1 and Table 2, respectively.
Dynamic changes of arterial blood and CMD glucose
and lactate levels during HL
Figure 1 illustrates changes of CMD (A) and arterial blood (B)
concentrations of lactate and glucose over time. Table 3 summa-
rizes the results of a mixed-effects regression model, showing that
HL was associated with a significant increase in the concentrations
of CMD glucose, CMD lactate, and arterial blood lactate.
Cerebral glucose-sparing effect of HL
was independent from systemic glucose
Systemic lactate can be converted into glucose via hepatic glu-
coneogenesis (GNG), which is activated in subjects with TBI21;
therefore, the observed increase in CMD glucose upon HL could be
at least partly secondary to systemic glucose increase via GNG,
which is subsequently transported to the brain. We found that al-
though arterial blood glucose increased slightly during HL, this was
not statistically significant ( p= 0.16; Table 3), thereby indicating
HL-related increase of cerebral extracellular glucose was not de-
pendent from arterial blood glucose, but rather predominantly at-
tributable to a cerebral sparing-glucose effect. Importantly,
systemic glucose always remained within the ranges for clinical
safety after TBI (6–10mmol/L), and it was not accompanied by a
significant change in intravenous insulin dose (Table 3).
Effect of HL on cerebral glucose according
to baseline brain LPR and CBF
The effect of HL on cerebral energetics was then examined in
predefined subgroups, according to patients’ baseline CMD LPR and
CBF, focusing this subgroup analysis on the main therapeutic end-
point, that is, CMD glucose. Figure 2 shows the dynamic changes of
CMD glucose over time, as a function of LPR (A) and CBF (B).
Mixed-effects model statistical analysis is summarized in Table 4.
When dichotomizing TBI subjects by baseline LPR, CMD glucose
increased significantly only in the subgroup of patients with baseline
elevated LPR >25 (n = 13; correlation coefficient +0.13mmol/L
[95% CI 0.08–0.19] during HL, p < 0.0001), whereas no significant
increase in CMD glucose was observed in patients with normal
LPR (n= 11; Table 4).
In contrast, CMD glucose increase following HL was comparable
in patients with oligemic CBF (n=8; average CBF 29.6 [range 24.7–
32] mL/100 g/min; correlation coefficient +0.13 [95% CI 0.04–0.21]
mmol/L during HL, p=0.003) and normal CBF (n= 14; average CBF
55.0 [41.6–82.8] mL/100 g/min; correlation coefficient +0.09 [95%
CI 0.04–0.14] mmol/L during HL, p=0.001).
Table 2. Baseline Cerebral and Systemic
Physiological Variables
Variable Value
CMD glucose, mmol/L 1.5 [0.5–4.3]
CMD lactate, mmol/L 2.8 [1.2–4.1]
CMD LPR 24 [13–45]
CBF, mL/100 g/min 49.8 [24.7–82.8]
Arterial blood glucose, mmol/L 7.4 [5.3–10.7]
Arterial blood lactate, mmol/L 1 [0.6–4.3]
Data are expressed as median and ranges.
CBF, cerebral blood flow; CMD, cerebral microdialysis; LPR, lactate/
pyruvate ratio.
FIG. 1. Dynamic changes of blood and cerebral extracellular levels of glucose and lactate from baseline, during and following hypertonic
lactate infusion (HL). The graph illustrates hourly brain extracellular (A) and arterial blood (B) concentrations of glucose (black lines) and
lactate (dashed lines) from baseline up to 12h following the start of 3-h intravenous HL. Data are expressed as mean – standard error of mean.
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Discussion
The main findings of this study can be summarized as follows:
1) HL improves cerebral energetics following TBI, independent
of systemic glucose; 2) cerebral glucose-sparing effect by HL
is significant only in patients with impaired cerebral oxidative
metabolism, as defined by CMD LPR >25; and 3) cerebral glu-
cose increase seems not to differ in patients with normal versus
oligemic CBF <32.5 mL/100 g/min.
Energy dysfunction after TBI
Glucose is the main energy substrate for the brain.3 Glucose
crosses the blood-brain barrier via specific glucose transporters
(GLUT), proportionally to baseline metabolism and demand.22
After TBI, energy demand is considerably augmented, causing an
increase in cerebral metabolic rate of glucose and so-called hy-
perglycolysis.23 This may ultimately lead to energy dysfunction or
crisis, with concomitant critical depletion of cerebral extracellular
glucose.1,2 This phenomenon may be further aggravated when
availability of systemic glucose is limited, such as by intensive
insulin therapy.24 Importantly, brain energy dysfunction and low
CMD glucose is associated with worse outcome after TBI.2 Current
therapeutic strategies for the management of secondary cerebral
damage after TBI have mainly been focused on improving cerebral
perfusion and controlling elevated ICP.25 Growing evidence
showing that brain energy dysfunction may be an important de-
terminant of prognosis provides a robust rationale to test other
therapeutic strategies aimed at improving neuroenergetics.26
Hypertonic lactate to treat energy dysfunction after TBI
Given the known deleterious role of hyperglycemia following
brain injury, the administration of glucose-containing solutions to
improve cerebral glucose cannot be recommended in this context
and has generally been avoided, partly also because of the risk of
increasing cerebral edema by the use of hypotonic solutions.
Lactate is an alternative energy substrate for the brain and can
even act as preferential fuel, particularly in conditions of increased
energy demand, such as those seen after injury.5,11,27 In vitro,
lactate allows neural function to be maintained and prevents neu-
ronal cell death upon hypoxia or glucose deprivation.28–30 Ex-
perimental blockade of lactate transport is associated with altered
cognitive function in animals, reinforcing the notion that lactate
may not only be an important substrate but also can serve as im-
portant signaling molecule for plasticity.31
Isotopic studies in patients with TBI appear to confirm that lactate
can be used as an energy source by the injured brain.32 In healthy
humans receiving HL, the contribution of exogenous systemic lac-
tate to brain metabolism might increase sixfold up to 60%.33 Sup-
plemental HL might therefore spare cerebral glucose34 and increase
cerebral resistance to strenuous efforts19 and hypoglycemia.35 A
large body of evidence suggests that HL exerts significant neuro-
protection in several models of experimental brain injury, including
TBI.12,13,36–38 In patients with TBI, HL might prevent secondary
intracranial hypertension6 and is more effective than mannitol in
controlling elevated ICP.7 Our group has recently shown that, in
addition to reduce ICP, HL might further improve cerebral ener-
getics in humans with TBI.8
Improvement of cerebral glucose by hypertonic lactate
seems dependent on baseline brain metabolic state
The LPR reflects the metabolic state of the tissue, and an ele-
vated LPR >25 is a marker of impaired cerebral oxidative metab-
olism suggesting elevated energy needs and/or compromised
metabolic pathways.9 Elevated LPR >25 was also associated with
neurological outcome in a large TBI cohort.10 In our study, more
than half of patients had an LPR >25, consistent with previous
studies.10 HL was associated with a significant and clinically
Table 3. Changes in Cerebral Extracellular
and Arterial Blood Concentrations of Glucose
and Lactate during Hypertonic Lactate Infusion
Variable Coefficient – SE 95% CI P value
Cerebral glucose, mmol/L 0.08 – 0.02 0.03–0.12 0.001
Cerebral lactate, mmol/L 0.35 – 0.07 0.22–0.48 <0.0001
Systemic glucose, mmol/L 0.12 – 0.08 -0.045–0.28 0.16
Insulin dose, units/h 0.05 – 0.19 -0.32–0.42 0.26
Systemic lactate, mmol/L 0.44 – 0.10 0.24–0.63 <0.0001
P values were calculated with a mixed-effects multilevel regression
model, to account for repeated measures across different patients over
time.
CI, confidence interval; SE, standard error.
FIG. 2. Dynamic changes of cerebral extracellular glucose concentrations from baseline, during and following hypertonic lactate
infusion (HL), according to patient subgroups, dichotomized by cerebral microdialysis (CMD) lactate/pyruvate ratio (LPR), or cerebral
blood flow (CBF). The graph shows changes (expressed as the % [delta] increase or decrease from baseline) of cerebral extracellular
glucose over time following a 3-h intravenous HL, according to patient baseline LPR (A, dichotomized as normal [CMD LPR £25;
n = 11] vs. elevated [LPR >25; n= 13]) and CBF (B, dichotomized as normal [CBF ‡32.5mL/100 g/min; n = 14] vs. oligemic [CBF
<32.5mL/100 g/min; n= 8]). Data are expressed as mean – standard error of mean.
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relevant increase in cerebral glucose only in patients with baseline
LPR >25, whereas no significant increase was observed when LPR
was <25 at the start of intervention. This supports the notion that
preferential lactate use with concomitant cerebral glucose sparing
was correlated to patient brain metabolic state and was clearly
apparent and clinically relevant (*50% CMD glucose increase) in
conditions where cerebral oxidative metabolism is impaired and
tissue energy demand is increased. We have previously shown that
CMD increase in pyruvate was also a function of baseline LPR.8
Altogether our findings suggest that CMD LPR can be used as a
marker and potential end-point for therapeutic interventions aimed
at improving neuroenergetics.
Effect of hypertonic lactate in conditions
of reduced CBF
Whether HL might still be effective in conditions of reduced or
impaired cerebral perfusion or oxygenation remains unclear. Of
interest, Rosafio and colleagures recently found that hypoxia in-
duces an overexpression of MCT4 in cultured astrocytes as well as
enhanced lactate production, an effect that is viewed as a neuro-
protective response.39 To answer this question, averaged values
from right and left hemispheres were calculated, to quantify
globally the extent of impaired CBF in each patient. We found that
the effect of HL on cerebral glucose increase did not seem to be
dependent on baseline CBF. However, average CBF was 29.6
(range 24.7–32) mL/100 g/min, therefore well above the recog-
nized definition of cerebral ischemia. Actually, some patients even
displayed hyperemic CBF. Therefore, our data clearly support the
finding that an elevated CBF does not seem to affect the metabolic
response to HL infusion. Our study therefore lacks sufficient power
to provide insights into the likely response of ischemic regions to
hypertonic lactate. Additional studies in patients with ischemic/
hemorrhagic stroke are needed.
Cerebral glucose-sparing effect of hypertonic lactate
is independent of systemic glucose
Supplemental systemic lactate may be metabolized into glu-
cose via hepatic and renal GNG. Following TBI, increased sys-
temic lactate metabolism and mobilization serves hepatic and
renal GNG and can be an important source of glucose.21 This
implies that increased CMD glucose following HL may be be-
cause of increased systemic glucose via induced GNG. Using a
mixed-effects regression model, we found that systemic glucose
did not increase significantly, which rather suggests a primary
increase of cerebral lactate metabolism and supports the notion
that lactate can indeed be used as a preferential energy substrate
over glucose, as previously reported.34,40 Preferential lactate
utilization will enable the ‘‘diversion’’ of glucose to become
available for other important non-energetic modulatory and pro-
tective functions in the setting of TBI, for example, the pentose
phosphate pathway.41
Study limitations
Cerebral metabolism was assessed regionally with CMD, but
we did not measure global cerebral metabolism with positron
emission tomography. This is a limitation that is compounded by
the fact that CMD technique is readily available in the critical care
setting and is part of standard patient care. Similarly, CBF was
measured with PCT, which explores CBF partially: only anterior
and middle cerebral vascular territories were assessed and chan-
ges in posterior cerebral vascular territories may be missed. PCT
has been previously validated by our group in patients with severe
TBI14–16 with good accuracy for the measurement of CBF when
compared with gold-standard techniques, such as xenon CT.42
CBF is dynamic especially within the first 72 h after injury, so this
could affect the overall findings and must be recognized as a
potential limitation of our study. Our definition of low CBF de-
serves further discussion. Oligemic CBF <32.5 mL/100 g/min was
about 2 standard deviations below normal CBF. Although this
threshold could be considered as only marginally low and above
the classical ischemic range (18–22mL/100 g/min), it has both
robust clinical16 and prognostic15 value. In addition, partly be-
cause of the modern setting of protocol-driven management, true
ischemic states are no longer common after TBI in the neurocri-
tical care phase.43 In our study, the ‘‘pro-energetic’’ effect of HL
did not seem to be reduced in conditions of limited CBF. How-
ever, we did not test HL in conditions of overt ischemia. The
inability to address this essential question is a serious limitation,
but we believe our findings at least provide a reasonable rationale
to further test the value of HL in patients with unequivocally
ischemic brain regions.
Conclusion
Our findings suggest that improvement of brain energetics dur-
ing infusion of HL is predominantly dependent on baseline cerebral
metabolic state and support the concept that an elevated LPR >25
after TBI is associated with a greater likelihood of brain glucose
increase as lactate is preferentially used as an energy substrate. In
this setting, LPR can be used as a diagnostic indication for HL. This
study also suggests that because HL effect on metabolism in tissue
with elevated LPR seems to be independent of CBF, perhaps it
would work well in tissue with non-ischemic LPR elevation and
could also be tested in other acute cerebral conditions where CBF
was more profoundly limited.
Table 4. Changes of Cerebral Extracellular Glucose during Hypertonic Lactate Infusion
Condition Coefficient – SE 95% CI P value
Cerebral LPR >25 (n = 13) 0.13 – 0.03 0.08–0.19 <0.0001
Cerebral LPR £25 (n = 11) 0.04 – 0.04 -0.05–0.13 0.327
CBF <32.5mL/100 g/min (n = 8)a 0.13 – 0.04 0.04–0.21 0.003
CBF ‡32.5mL/100 g/min (n = 14)a 0.09 – 0.03 0.04–0.14 0.001
Changes are according to baseline CBF (dichotomized as oligemic <32.5mL/100 g/min vs. normal) and cerebral extracellular LPR (elevated >25 vs.
normal). P values were calculated with mixed-effects multilevel regression model, to account for repeated measures across different patients over time.
aPCT data from two patients missing.
CBF, cerebral blood flow; CI, confidence interval; LPR, cerebral extracellular lactate/pyruvate ratio; SE, standard error.
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